|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2008.16.1307 on June 9 2008 © 2008 American Society of Clinical Oncology.
Primary Cutaneous Small/Medium CD4+ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome
From the Hematopathology Section, Department of Pathology, Department of Hematology, and Dermatology, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain Corresponding author: Elias Campo, MD, Hematopathology Section, Hospital Clínic, Villarroel 170, 08036-Barcelona, Spain; e-mail: ecampo{at}clinic.ub.es Purpose To define the clinical and pathologic characteristics of primary cutaneous small/medium CD4+ T-cell lymphoma (PCSM-TCL) and identify parameters of prognostic significance. Patients and Methods We have investigated 24 patients with primary cutaneous lymphomas composed of small/medium mature T-cells with a βF1, CD3, CD4+ and/or noncytotoxic, CD8– and CD30– phenotype. The proliferation index and CD8+ infiltrating cells were quantified with an automated image analysis system.
Results Sixteen patients presenting with solitary or localized plaques or small nodules (< 3 cm) had an indolent course. Only three patients experienced repeated cutaneous relapses, and none of them died as a result of the disease after 1 to 168 months (median, 17 months) of follow-up. The tumors had a low proliferation (median Ki-67, 9% ± 5%) and an intense infiltrate of reactive CD8+ (median, 20% ± 11.7%). Five patients presenting with rapidly evolving large tumors or nodules ( Conclusion PCSM-TCL is a heterogeneous group of tumors with differentiated clinical and pathological characteristics with impact in the outcome of the patients. published online ahead of print at www.jco.org on June 9, 2008. Supported by the Spanish Comisión Interministerial de Ciencia y Tecnología SAF05-5855 (E.C.), Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (PI050458-TE and PI070409-ALG), Red Temática de Investigación Cooperativa de Cáncer (RET 20 39), and Instituto de Salud Carlos III (where O.B. is a fellow). Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|